These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9351533)

  • 21. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.
    Ludlam CA
    Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779
    [No Abstract]   [Full Text] [Related]  

  • 22. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recombinant factor VIII. An introduction to recombinant DNA technology and the first results published in the replacement treatment of hemophilia A].
    Juárez Giménez JC; Montoro Ronsano JB; Tusell JM
    Med Clin (Barc); 1994 Nov; 103(15):591-5. PubMed ID: 7990527
    [No Abstract]   [Full Text] [Related]  

  • 24. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 25. How we choose factor VIII to treat hemophilia.
    Mannucci PM; Mancuso ME; Santagostino E
    Blood; 2012 May; 119(18):4108-14. PubMed ID: 22411872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who should use recombinant factor VIII?
    Hoots K
    Ann Hematol; 1994; 68 Suppl 3():S65-8. PubMed ID: 8180258
    [No Abstract]   [Full Text] [Related]  

  • 28. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
    van der Bom JG; Gouw SC; Rosendaal FR
    Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
    [No Abstract]   [Full Text] [Related]  

  • 31. Factor VIII assays in haemophilia a patients treated with ReFacto.
    Sukhu K; Harrison P; Keeling D
    Br J Haematol; 2003 Apr; 121(2):379-80. PubMed ID: 12694265
    [No Abstract]   [Full Text] [Related]  

  • 32. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 33. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products.
    VanAken WG
    Transfus Med Rev; 1997 Jan; 11(1):6-14. PubMed ID: 9031486
    [No Abstract]   [Full Text] [Related]  

  • 35. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
    Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acquired haemophilia with recombinant porcine factor VIII: A successful strategy in a patient with unstable angina.
    Owen M; Gidley G; Horn EH
    Haemophilia; 2019 Mar; 25(2):e94-e97. PubMed ID: 30604899
    [No Abstract]   [Full Text] [Related]  

  • 37. Progressing towards optimal management of haemophilia A patients with inhibitors. Foreword.
    Tarantino MD
    Haemophilia; 2013 Jan; 19 Suppl 1():1. PubMed ID: 23278992
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and introduction of recombinant factor VIII--a clinician's experience.
    Lusher JM
    Haemophilia; 2012 Jul; 18(4):483-6. PubMed ID: 22512315
    [No Abstract]   [Full Text] [Related]  

  • 39. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Haemophilia A therapy of adults. Actual treatment situation in a haemophilia centre].
    Siegmund B; Richter H; Pollmann H
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S32-4. PubMed ID: 21042667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.